124 related articles for article (PubMed ID: 22889968)
1. Impact of CYP3A5 genetic polymorphism on cross-reactivity in tacrolimus chemiluminescent immunoassay in kidney transplant recipients.
Hirano K; Naito T; Mino Y; Takayama T; Ozono S; Kawakami J
Clin Chim Acta; 2012 Dec; 414():120-4. PubMed ID: 22889968
[TBL] [Abstract][Full Text] [Related]
2. A comparison of the effects of CYP3A5 polymorphism on tacrolimus blood concentrations measured by 4 immunoassay methods in renal transplant patients.
Akamine Y; Kagaya H; Ohkubo T; Satoh S; Miura M
J Clin Pharm Ther; 2018 Apr; 43(2):181-188. PubMed ID: 28891077
[TBL] [Abstract][Full Text] [Related]
3. Effect of CYP3A5 genotype on renal allograft recipients treated with tacrolimus.
Chen JS; Li LS; Cheng DR; Ji SM; Sun QQ; Cheng Z; Wen JQ; Sha GZ; Liu ZH
Transplant Proc; 2009 Jun; 41(5):1557-61. PubMed ID: 19545678
[TBL] [Abstract][Full Text] [Related]
4. The effect of CYP3A5 polymorphisms on the pharmacokinetics of tacrolimus in adolescent kidney transplant recipients.
Tirelli S; Ferraresso M; Ghio L; Meregalli E; Martina V; Belingheri M; Mattiello C; Torresani E; Edefonti A
Med Sci Monit; 2008 May; 14(5):CR251-254. PubMed ID: 18443548
[TBL] [Abstract][Full Text] [Related]
5. Impact of cytochrome p450 3A5 genetic polymorphism on tacrolimus doses and concentration-to-dose ratio in renal transplant recipients.
Thervet E; Anglicheau D; King B; Schlageter MH; Cassinat B; Beaune P; Legendre C; Daly AK
Transplantation; 2003 Oct; 76(8):1233-5. PubMed ID: 14578760
[TBL] [Abstract][Full Text] [Related]
6. P450 oxidoreductase *28 (POR*28) and tacrolimus disposition in pediatric kidney transplant recipients--a pilot study.
Gijsen VM; van Schaik RH; Soldin OP; Soldin SJ; Nulman I; Koren G; de Wildt SN
Ther Drug Monit; 2014 Apr; 36(2):152-8. PubMed ID: 24089076
[TBL] [Abstract][Full Text] [Related]
7. Reduced variability of tacrolimus trough level in once-daily tacrolimus-based Taiwanese kidney transplant recipients with high-expressive genotype of cytochrome P450 3A5.
Wu MJ; Chang CH; Cheng CY; Shu KH; Chen CH; Cheng CH; Yu TM; Chuang YW; Huang ST; Tsai SF; Ho HC; Li JR; Shiu YN; Fu YC
Transplant Proc; 2014; 46(2):403-5. PubMed ID: 24655974
[TBL] [Abstract][Full Text] [Related]
8. Influence of CYP3A5 genetic polymorphism on tacrolimus daily dose requirements and acute rejection in renal graft recipients.
Quteineh L; Verstuyft C; Furlan V; Durrbach A; Letierce A; Ferlicot S; Taburet AM; Charpentier B; Becquemont L
Basic Clin Pharmacol Toxicol; 2008 Dec; 103(6):546-52. PubMed ID: 19067682
[TBL] [Abstract][Full Text] [Related]
9. Tacrolimus dose requirement in relation to donor and recipient ABCB1 and CYP3A5 gene polymorphisms in Chinese liver transplant patients.
Wei-lin W; Jing J; Shu-sen Z; Li-hua W; Ting-bo L; Song-feng Y; Sheng Y
Liver Transpl; 2006 May; 12(5):775-80. PubMed ID: 16628701
[TBL] [Abstract][Full Text] [Related]
10. Impact of MDR1 and CYP3A5 on the oral clearance of tacrolimus and tacrolimus-related renal dysfunction in adult living-donor liver transplant patients.
Fukudo M; Yano I; Yoshimura A; Masuda S; Uesugi M; Hosohata K; Katsura T; Ogura Y; Oike F; Takada Y; Uemoto S; Inui K
Pharmacogenet Genomics; 2008 May; 18(5):413-23. PubMed ID: 18408564
[TBL] [Abstract][Full Text] [Related]
11. Impact of tacrolimus intraindividual variability and CYP3A5 genetic polymorphism on acute rejection in kidney transplantation.
Ro H; Min SI; Yang J; Moon KC; Kim YS; Kim SJ; Ahn C; Ha J
Ther Drug Monit; 2012 Dec; 34(6):680-5. PubMed ID: 23149441
[TBL] [Abstract][Full Text] [Related]
12. Significant impact of gene polymorphisms on tacrolimus but not cyclosporine dosing in Asian renal transplant recipients.
Loh PT; Lou HX; Zhao Y; Chin YM; Vathsala A
Transplant Proc; 2008 Jun; 40(5):1690-5. PubMed ID: 18589174
[TBL] [Abstract][Full Text] [Related]
13. Influence of CYP3A5 and MDR1 polymorphisms on tacrolimus concentration in the early stage after renal transplantation.
Zhang X; Liu ZH; Zheng JM; Chen ZH; Tang Z; Chen JS; Li LS
Clin Transplant; 2005 Oct; 19(5):638-43. PubMed ID: 16146556
[TBL] [Abstract][Full Text] [Related]
14. Effect of CYP3A51/3 polymorphism on blood pressure in renal transplant recipients.
Torio A; Auyanet I; Montes-Ares O; Guerra RM; Fernandez EJ; Perez MA; Ramirez A; Checa MD
Transplant Proc; 2012 Nov; 44(9):2596-8. PubMed ID: 23146466
[TBL] [Abstract][Full Text] [Related]
15. Pharmacogenotyping of CYP3A5 in predicting dose-adjusted trough levels of tacrolimus among Malaysian kidney-transplant patients.
Hamzah S; Teh LK; Siew JS; Ahmad G; Wong HS; Zakaria ZA; Salleh MZ
Can J Physiol Pharmacol; 2014 Jan; 92(1):50-7. PubMed ID: 24383873
[TBL] [Abstract][Full Text] [Related]
16. Effects of Genetic Polymorphism in CYP3A4 and CYP3A5 Genes on Tacrolimus Dose Among Kidney Transplant Recipients.
Yousef AM; Qosa H; Bulatova N; Abuhaliema A; Almadhoun H; Khayyat G; Olemat M
Iran J Kidney Dis; 2016 May; 10(3):156-63. PubMed ID: 27225724
[TBL] [Abstract][Full Text] [Related]
17. Genetic polymorphisms of CYP3A5 genes and concentration of the cyclosporine and tacrolimus.
Zhao Y; Song M; Guan D; Bi S; Meng J; Li Q; Wang W
Transplant Proc; 2005; 37(1):178-81. PubMed ID: 15808586
[TBL] [Abstract][Full Text] [Related]
18. Association between CYP3A5 genotypes in graft liver and increase in tacrolimus biotransformation from steroid treatment in living-donor liver transplant patients.
Hosohata K; Uesugi M; Hashi S; Hosokawa M; Inui K; Matsubara K; Ogawa K; Fujimoto Y; Kaido T; Uemoto S; Masuda S
Drug Metab Pharmacokinet; 2014; 29(1):83-9. PubMed ID: 23955548
[TBL] [Abstract][Full Text] [Related]
19. Association between CYP3A5 polymorphisms and blood pressure in kidney transplant recipients receiving calcineurin inhibitors.
Ferraresso M; Turolo S; Ghio L; Tirelli AS; Belingheri M; Villa R; Groppali E; Edefonti A
Clin Exp Hypertens; 2011; 33(6):359-65. PubMed ID: 21851254
[TBL] [Abstract][Full Text] [Related]
20. Benefits of minimizing immunosuppressive dosage according to cytochrome P450 3A5 genotype in liver transplant patients: findings from a single-center study.
Wang L; Li N; Wang MX; Lu SC
Genet Mol Res; 2015 Apr; 14(2):3191-9. PubMed ID: 25966085
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
